secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001558370-25-001439
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences Q4 2024 net revenue $201.3M, FY $714.7M; guides 2025 $820-860M
--------------------------------------------------------------------------------

- Q4 2024 net product revenue $201.3M (+20% YoY); FY 2024 net revenue $714.7M (+23% YoY).
- Q4 GAAP net income $49.5M ($0.85 diluted EPS); non-GAAP adjusted net income $63.0M ($1.08 diluted EPS).
- 2025 WAKIX net revenue guidance set at $820M-$860M; on track for potential $1B+ narcolepsy opportunity.
- Phase 3 topline for ZYN002 in Fragile X syndrome expected Q3 2025; pitolisant HD trials to start Q4 2025.
- Settled first ANDA litigation with Novugen; generic license begins Jan 2030 or earlier under certain conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837025001439/0001558370-25-001439-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837025001439/hrmy-20250225x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-001439

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer